



PEI Pharmacare  
P.O. Box 2000  
Charlottetown, PE  
C1A 7N8  
[www.princeedwardisland.ca](http://www.princeedwardisland.ca)



Programmes provinciaux de médicaments  
C.P. 2000  
Charlottetown, PE  
C1A 7N8  
[www.princeedwardisland.ca](http://www.princeedwardisland.ca)

# PEI Pharmacare Bulletin

Issue (2024 - 16)

September 24, 2024

## PEI BIOSIMILAR INITIATIVE REMINDERS

This is a final reminder that effective October 1, 2024, Copaxone<sup>®</sup>, Enbrel<sup>®</sup>, Humira<sup>®</sup>, Remicade<sup>®</sup> and Rituxan<sup>®</sup> will no longer be eligible benefits (unless approved under the Biosimilar Exemption policy) under any PEI Pharmacare drug program.

Additionally, as communicated in the August 13, 2024, Pharmacare bulletin, ustekinumab (Stelara<sup>®</sup>) has been added to the PEI Biosimilar Initiative.

- For ustekinumab-naïve patients whose ustekinumab therapy is initiated after August 26, 2024, an ustekinumab biosimilar will be the product approved.
- Patients with existing PEI Pharmacare coverage for Stelara<sup>®</sup> will need to switch to a biosimilar version before August 31, 2025, or by the renewal date of their current special authorization, whichever is earlier, to maintain coverage through PEI Pharmacare.